Citations (30)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (7)
Mahmoud R Gaballa, Jacob P Laubach, Robert L Schlossman, Katherine Redman, Kimberly Noonan, Constantine S Mitsiades, Irene M Ghobrial, Nikhil Munshi, Kenneth C Anderson & Paul G Richardson. (2012) Management of myeloma-associated renal dysfunction in the era of novel therapies. Expert Review of Hematology 5:1, pages 51-68.
Read now
Read now
Louis M Pelus & Sherif S Farag. (2011) Increased mobilization and yield of stem cells using plerixafor in combination with granulocyte-colony stimulating factor for the treatment of non-Hodgkin’s lymphoma and multiple myeloma. Stem Cells and Cloning: Advances and Applications 4, pages 11-22.
Read now
Read now
Javier de la Rubia & Mónica Roig. (2011) Bortezomib for previously untreated multiple myeloma. Expert Review of Hematology 4:4, pages 381-398.
Read now
Read now
Don M. Benson$suffix/text()$suffix/text(), Kathryn Panzner, Mehdi Hamadani, Craig C. Hofmeister, Courtney E. Bakan, Megan K. Smith, Pat Elder, David Krugh, Lynn O'Donnell & Steven M. Devine. (2010) Effects of induction with novel agents versus conventional chemotherapy on mobilization and autologous stem cell transplant outcomes in multiple myeloma. Leukemia & Lymphoma 51:2, pages 243-251.
Read now
Read now
Paul G Richardson, Constantine Mitsiades, Robert Schlossman, Irene Ghobrial, Teru Hideshima, Nikhil Munshi & Kenneth C Anderson. (2008) Bortezomib in the front-line treatment of multiple myeloma. Expert Review of Anticancer Therapy 8:7, pages 1053-1072.
Read now
Read now
Jan Sterz, Ivana von Metzler, Jens-Claus Hahne, Britta Lamottke, Jessica Rademacher, Ulrike Heider, Evangelos Terpos & Orhan Sezer. (2008) The potential of proteasome inhibitors in cancer therapy. Expert Opinion on Investigational Drugs 17:6, pages 879-895.
Read now
Read now
Morie A. Gertz. (2008) Current therapy of myeloma induced renal failure. Leukemia & Lymphoma 49:5, pages 833-834.
Read now
Read now
Articles from other publishers (23)
Eyal Lebel, Katherine Lajkosz, Esther Masih-Khan, Donna Reece, Suzanne Trudel, Rodger Tiedemann, Anca Prica, Vishal Kukreti & Christine Chen. (2023) The Impact of CD34+ Cell Collection Yields for Autologous Transplant on Survival Outcomes in Multiple Myeloma. Clinical Lymphoma Myeloma and Leukemia 23:11, pages 850-856.
Crossref
Crossref
Bhausaheb Bagal, Anant Gokarn, Sachin Punatar, Shashank Das, Avinash Bonda, Lingaraj Nayak, Akanksha Chichra, Sadhana Kannan, Libin J. Mathew, Prashant Tembhare, Nikhil Patkar, Minal Poojary, Shashank Ojha, Papagudi Ganesan Subramanian, Sumeet Gujral & Navin Khattry. (2020) Bortezomib and cyclophosphamide based chemo-mobilization in multiple myeloma. International Journal of Hematology 112:6, pages 835-840.
Crossref
Crossref
Efrat Luttwak, Odelia Amit, Irit Avivi, Svetlana Trestman, Rinat Eshel, Yael C. Cohen & Ron Ram. (2020) Bortezomib washout duration prior to stem cell mobilization in patients with newly diagnosed multiple myeloma. European Journal of Haematology 105:1, pages 30-34.
Crossref
Crossref
Sunil Abhyankar, Philip Lubanski, Shaun DeJarnette, Dean Merkel, Jennifer Bunch, Kelly Daniels, Omar Aljitawi, Tara Lin, Sid Ganguly & Joseph McGuirk. (2016) A novel hematopoietic progenitor cell mobilization regimen, utilizing bortezomib and filgrastim, for patients undergoing autologous transplant. Journal of Clinical Apheresis 31:6, pages 559-563.
Crossref
Crossref
Bhanu K. Patibandla, Akshita Narra, Ahmad A. Alwassia, Anthony Bartley, Gurprataap S. Sandhu, James Rooney & Robert M. Black. (2014) Case Report on Renal Failure Reversal in Lambda Chain Multiple Myeloma with Bortezomib and Dexamethasone. Case Reports in Nephrology 2014, pages 1-6.
Crossref
Crossref
Morie A. Gertz & Craig B. Reeder. 2014. Multiple Myeloma. Multiple Myeloma
101
123
.
S Manier, M Barthelemy, G Fouquet, C Prod’homme, E Le Ray, P Samarcq, M P Noel, L Terriou, T Facon, C Cossment, F Boulanger & X Leleu. (2012) Reduced steady state-based peripheral blood stem cell harvest rate in multiple myeloma treated with bortezomib-based induction regimens. Leukemia 26:12, pages 2552-2554.
Crossref
Crossref
Andrzej J. JakubowiakDominik DytfeldKent A. GriffithDaniel LebovicDavid H. VesoleSundar Jagannath, Ammar Al-ZoubiTara AndersonBrian NordgrenKristen Detweiler-ShortKeith Stockerl-Goldstein, Asra AhmedTerri JobkarDiane E. DureckiKathryn McDonnellMelissa MietzelDaniel CourielMark KaminskiRavi Vij. (2012) A phase 1/2 study of carfilzomib in combination with lenalidomide and low-dose dexamethasone as a frontline treatment for multiple myeloma. Blood 120:9, pages 1801-1809.
Crossref
Crossref
Dixie-Lee Esseltine & George Mulligan. (2012) An Historic Perspective of Proteasome Inhibition. Seminars in Hematology 49:3, pages 196-206.
Crossref
Crossref
James J. Driscoll, Jason Burris & Christina M. Annunziata. (2012) Targeting the Proteasome With Bortezomib in Multiple Myeloma. American Journal of Therapeutics 19:2, pages 133-144.
Crossref
Crossref
A Dispenzieri, S Jacobus, D H Vesole, N Callandar, R Fonseca & P R Greipp. (2010) Primary therapy with single agent bortezomib as induction, maintenance and re-induction in patients with high-risk myeloma: results of the ECOG E2A02 trial. Leukemia 24:8, pages 1406-1411.
Crossref
Crossref
Meletios A. Dimopoulos, Christine Chen, Efstathios Kastritis, Maria Gavriatopoulou & Steven P. Treon. (2010) Bortezomib as a Treatment Option in Patients With Waldenström Macroglobulinemia. Clinical Lymphoma Myeloma and Leukemia 10:2, pages 110-117.
Crossref
Crossref
Heinz Ludwig, Meral Beksac, Joan Bladé, Mario Boccadoro, Jamie CavenaghMichele Cavo, Meletios Dimopoulos, Johannes Drach, Hermann Einsele, Thierry Facon, Hartmut Goldschmidt, Jean-Luc Harousseau, Urs Hess, Nicolas Ketterer, Martin Kropff, Larisa Mendeleeva, Gareth MorganAntonio Palumbo, Torben Plesner, Jesús San Miguel, Ofer Shpilberg, Pia SondergeldPieter Sonneveld & Sonja Zweegman. (2010) Current Multiple Myeloma Treatment Strategies with Novel Agents: A European Perspective. The Oncologist 15:1, pages 6-25.
Crossref
Crossref
Martin Kropff, Peter Liebisch, Stefan Knop, Katja Weisel, Hannes Wand, Claudia-Nanette Gann, Wolfgang E. Berdel & Herrmann Einsele. (2009) DSMM XI study: dose definition for intravenous cyclophosphamide in combination with bortezomib/dexamethasone for remission induction in patients with newly diagnosed myeloma. Annals of Hematology 88:11, pages 1125-1130.
Crossref
Crossref
Sundar Jagannath, Brian G. M. Durie, Jeffrey Lee Wolf, Elber S. Camacho, David Irwin, Jose Lutzky, Marti McKinley, Phyllis Potts, Afshin Eli Gabayan, Amitabha Mazumder, John Crowley & Robert Vescio. (2009) Extended follow-up of a phase 2 trial of bortezomib alone and in combination with dexamethasone for the frontline treatment of multiple myeloma. British Journal of Haematology 146:6, pages 619-626.
Crossref
Crossref
Paul G. RichardsonWanling XieConstantine MitsiadesAsher A. Chanan-KhanSagar LonialHani HassounDavid E. AviganAnne Louise OaklanderDavid J. KuterPatrick Y. WenSantosh KesariHannah R. BriembergRobert L. SchlossmanNikhil C. MunshiL. Thompson HeffnerDeborah DossDixie-Lee EsseltineEdie WellerKenneth C. AndersonAnthony A. Amato. (2009) Single-Agent Bortezomib in Previously Untreated Multiple Myeloma: Efficacy, Characterization of Peripheral Neuropathy, and Molecular Correlations With Response and Neuropathy. Journal of Clinical Oncology 27:21, pages 3518-3525.
Crossref
Crossref
Gianfranco Giglio, Sante Romito, Francesco Carrozza, Michela Musacchio, Giustino Antuzzi, Rosanna Gigli, Marilù Magri, Pasqua Bavaro, Paolo Di Bartolomeo, Mario Dell’Isola & Patrizia Accorsi. (2009) Successful mobilization of peripheral blood stem cells with bortezomib + high-dose cyclophosphamide + G-CSF in a light chain myeloma patient after failure with Total Therapy 2. International Journal of Hematology 90:1, pages 81-86.
Crossref
Crossref
Sagar Lonial & Jamie Cavenagh. (2009) Emerging combination treatment strategies containing novel agents in newly diagnosed multiple myeloma. British Journal of Haematology 145:6, pages 681-708.
Crossref
Crossref
G Cook, J M Bird & D I Marks. (2008) In pursuit of the allo-immune response in multiple myeloma: where do we go from here?. Bone Marrow Transplantation 43:2, pages 91-99.
Crossref
Crossref
Lili Zhou, Jian Hou, Weijun Fu, Dongxing Wang, Zhenggang Yuan & Hua Jiang. (2008) Arsenic trioxide and 2-methoxyestradiol reduce β-catenin accumulation after proteasome inhibition and enhance the sensitivity of myeloma cells to Bortezomib. Leukemia Research 32:11, pages 1674-1683.
Crossref
Crossref
Joan Bladé & Laura Rosiñol. 2009. Treatment of Multiple Myeloma and Related Disorders. Treatment of Multiple Myeloma and Related Disorders
76
85
.
Béla Telek, Leonóra Méhes, Péter Batár, Attila Kiss & Miklós Udvardy. (2008) Effective PAD (bortezomib, doxorubicine, dexamethasone) treatment of a patient with plasma cell leukaemia developed after autologous stem cell transplantation. Orvosi Hetilap 149:41, pages 1957-1959.
Crossref
Crossref
. (2008) Current Awareness in Hematological Oncology. Hematological Oncology 26:2, pages 115-122.
Crossref
Crossref